Lupin Q3 Results Net Loss Rs 835 Crore

Lupin Q3 Results Net Loss Rs 835 Crore

Lupin Q3 Results Net Loss Rs 835 Crore

Lupin Q3 Results, due to exceptional items including Gavis portfolio impairment, Lupin reported Q3 results with a net loss of Rs 835 crore. Meanwhile, last fiscal year, the company reported a net loss of Rs 151.75 crore. 

In the quarter under review, the company’s consolidated revenues amounted to Rs 3,716 crore. Whereas in last fiscal it amounted to Rs 3,821,19 crore. 

Meanwhile, the company MD Nilesh Gupta said, “The figures are many once a year this quarter. Exceptional, including the impairment of Gavis portfolio and our divestiture of Kyowa, reported significantly.”

He added the company growth would increase its market resilience, stabilizing the American general basis market and growth in new launches. Gupta also stated that “Quality remains our highest priority, we are making progress steadily in remediating our manufacturing footprint.”

In addition, the entire Lupin stake completed in Kyowa Pharmaceutical Industry Co Ltd on last fiscal 17th December 2019. The transaction resulted in Rs 1,291,1 crore pre-tax benefit. 

With the shift of Gavis pipeline value, it agreed to impair some intangible assets acquired under Gavis ‘ acquisition which resulted in an exceptionally high loss (pre-tax) of Rs 1,579.8 crore. Besides, the Lupin share trading with a loss of 19.50 points reached 702.40 INR with 2.70% down. Its previous close 721.90 INR.

Related posts

Ramco Cements Share Value Drops 3%

nagalavanya

TLTRO 2.0 First sale on April 23rd conduct by RBI for Rs 25,000 crore

mahesh

Jet Airways share climbs 5% after ED register case against Naresh Goyal

Tarun